The EuMederis platform technology (EuPort™) is directed at improvements in the bioavailability and duration of action of peptide therapeutics. This technology is designed to be effective for the administration of peptides by subcutaneous, intranasal and oral routes.
When used for subcutaneous administration, EuPort™-modified products form a micellar/liquid crystal depot and then reversibly bind to serum albumin for extended circulation in the body (fully flexible for pharmacodynamic profiles lasting hours to days).
Transmucosal bioavailability is facilitated by the surfactant like character of the new chemical entity achieved by linkage to the EuPort™ modification.
The novelty and efficacy of our proprietary modifications allows broad entry into a wide range of intellectual property space for the resultant pharmaceutical candidates. International search reports support the complete novelty of the EuPort™ modification and broad international patent filings have been allowed.